Marksans Pharma Ltd
NSE:MARKSANS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Marksans Pharma Ltd
NSE:MARKSANS
|
IN |
|
Stanley Black & Decker Inc
NYSE:SWK
|
US |
|
A
|
Arrivent Biopharma Inc
NASDAQ:AVBP
|
US |
|
M
|
Markel Group Inc
SWB:MKV
|
US |
|
Z
|
Zynerba Pharmaceuticals Inc
F:6ZY
|
US |
|
Pacific Century Regional Developments Ltd
SGX:P15
|
SG |
|
Aeroports de Paris SA
PAR:ADP
|
FR |
Wall Street
Price Targets
MARKSANS Price Targets Summary
Marksans Pharma Ltd
According to Wall Street analysts, the average 1-year price target for
MARKSANS
is 229.5 INR
with a low forecast of 212.1 INR and a high forecast of 252 INR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is MARKSANS's stock price target?
Price Target
229.5
INR
According to Wall Street analysts, the average 1-year price target for
MARKSANS
is 229.5 INR
with a low forecast of 212.1 INR and a high forecast of 252 INR.
What is Marksans Pharma Ltd's Revenue forecast?
Projected CAGR
14%
For the last 13 years the
compound annual growth rate for
Marksans Pharma Ltd's revenue is
17%.
The projected
CAGR
for the next 3 years is
14%.
What is Marksans Pharma Ltd's Operating Income forecast?
Projected CAGR
12%
The
compound annual growth rate
of Marksans Pharma Ltd's operating income for the next 3 years is
12%.
What is Marksans Pharma Ltd's Net Income forecast?
Projected CAGR
15%
The
compound annual growth rate
of Marksans Pharma Ltd's net income for the next 3 years is
15%.
